RASAL1 Inhibitors
RASAL1 inhibitors belong to a distinct chemical class that plays a pivotal role in modulating cellular signaling pathways, particularly those associated with the RAS family of proteins. RASAL1, short for RAS protein activator like 1, serves as a critical regulator in the intricate network of cellular processes, exerting influence on cell growth, differentiation, and survival. The inhibitors designed to target RASAL1 operate at the molecular level, aiming to disrupt the enzymatic activity or interactions that facilitate the regulatory function of RASAL1 within the cellular milieu.
RASAL1 inhibitors are characterized by their ability to selectively bind to the active site or allosteric pockets of RASAL1 proteins, impeding their catalytic function or altering their conformational dynamics. The intricate design of these inhibitors often involves a combination of small molecules or peptides that can effectively penetrate cellular membranes and interact specifically with RASAL1. Researchers employ a variety of structural and computational approaches to design and optimize RASAL1 inhibitors, aiming to enhance their binding affinity, bioavailability, and pharmacokinetic properties. The development of such inhibitors not only contributes to our understanding of cellular signaling pathways but also holds promise for potential applications in various fields, including basic research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
This molecule acts by displacing Ras from the cell membrane, thus preventing its activation and the subsequent signaling cascade where RASAL1 is involved. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib inhibits farnesyltransferase, an enzyme required for the post-translational modification of Ras proteins, impacting RASAL1 regulatory pathways. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Similar to tipifarnib, lonafarnib is a farnesyltransferase inhibitor, hence it can disrupt the post-translational processing of Ras affecting RASAL1. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
As a MEK inhibitor, cobimetinib targets downstream effectors in the Ras/Raf/MEK/ERK pathway, in which RASAL1 is an upstream regulator. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is another MEK inhibitor that indirectly affects RASAL1's activity by inhibiting downstream signaling components of the Ras pathway. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Binimetinib, a MEK inhibitor, would impact the signaling pathways influenced by RASAL1 by preventing the phosphorylation of MEK. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
This pan-RAF inhibitor disrupts the Raf kinases acting downstream of Ras and, by extension, could modulate the activity of RASAL1. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib targets the BRAF kinase, another component of the Ras pathway, potentially affecting the regulatory role of RASAL1. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
An ERK inhibitor that would indirectly affect RASAL1 activity by inhibiting the downstream signaling molecule ERK in the Ras pathway. | ||||||